Among these, sunitinib (N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide) reduced MAPK/ERK pathway activity in RET-expressing BC cell lines (7). The gene discussed is RET; the disease is breast cancer.